62 completed, 14 terminated, 5 recruiting, 4 unknown. 21 Phase 2, 19 Phase 4, 14 Phase 3, 7 Phase 1, 4 Not applicable.
Follow Natalizumab: new trials by email Literature Review of Natalizumab trials Research Report on Natalizumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Natalizumab for the Prevention of ICANS in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma Receiving CAR T-Cell Therapy Axicabtagene Ciloleucel, Biospecimen Collection, Brexucabtagene Autoleucel - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Mantle Cell Lymphoma | Phase 2 | Recruiting | University of Michigan Rogel Cancer Center | 26 | 2026-11-01 | 2026-10-23 |
| Natalizumab in Recurrent, Refractory or Progressive Pulmonary Metastatic Osteosarcoma Natalizumab - Pulmonary Metastatic Osteosarcoma (pOS) | Phase 1 / Phase 2 | Withdrawn | Case Comprehensive Cancer Center | 2024-12-01 | 2025-01-15 | |
| Pregnancy Exposure Registry for Vumerity (Diroximel Fumarate) Diroximel Fumarate, Avonex, Tysabri - Multiple Sclerosis | Recruiting | Biogen | 908 | 2023-10-27 | 2026-08-11 | |
| Motixafortide and Natalizumab to Mobilize CD34+ Hematopoietic Stem Cells for Gene Therapies in Sickle Cell Disease (SCD) Motixafortide, Natalizumab, Leukapheresis - Sickle Cell Disease | Phase 1 | Completed | Washington University School of Medicine | 10 | 2023-07-07 | 2025-08-11 |
| A Study Utilising Data From European Union (EU) National Multiple Sclerosis (MS) Registries to Assess the Incidence of Anti-Natalizumab Antibody Among Participants Who Receive Subcutaneous Administration of Natalizumab for Treatment of Relapsing-remitting Multiple Sclerosis (RRMS) Natalizumab - Multiple Sclerosis | Active not recruiting | Biogen | 400 | 2023-06-30 | 2026-05-13 | |
| A Study of End of Dose Phenomena in Subcutaneous Natalizumab Treated Multiple Sclerosis (MS) Participants Natalizumab - Multiple Sclerosis | Terminated | Biogen | 34 | 2023-02-08 | 2024-09-19 | |
| A Study to Investigate the Radiological Onset of Action After Treatment Initiation With Subcutaneous (SC) Natalizumab in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) Natalizumab - Multiple Sclerosis, Relapsing-Remitting | Phase 4 | Terminated | Biogen | 1 | 2023-01-23 | 2024-06-21 |
| The 'Wearing Off' Effect of DMT ocrelizumab, natalizumab, ofatumumab - Multiple Sclerosis | Completed | Novartis Pharmaceuticals | 39 | 2023-01-10 | 2023-06-01 | |
| Natalizumab for the Treatment of People With Inflammatory Demyelination Suggestive of Multiple Sclerosis, or Definite Multiple Sclerosis, at First Presentation (AttackMS) Tyruko Injectable Product, Placebo - Multiple Sclerosis, Clinically Isolated Syndrome of Demyelination | Phase 2 | Recruiting | Queen Mary University of London | 40 | 2022-12-01 | 2026-01-07 |
| Natalizumab and Chronic Inflammation Natalizumab 300 MG in 15 ML Injection - Multiple Sclerosis | Phase 4 | Terminated | Vanderbilt University Medical Center | 1 | 2022-09-16 | 2024-04-18 |
| A Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of Natalizumab (BG00002) Administered Subcutaneously to Japanese Participants With Relapsing-Remitting Multiple Sclerosis Natalizumab - Multiple Sclerosis, Relapsing-Remitting | Phase 3 | Terminated | Biogen | 21 | 2022-04-26 | 2025-11-25 |
| A Study for Tysabri Participant Preference Natalizumab - Relapsing-Remitting Multiple Sclerosis (RRMS) | Completed | Biogen | 318 | 2021-10-12 | 2024-05-17 | |
| A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY®) in Participants Who Took it During Pregnancy And About the Health of Their Babies Diroximel Fumarate, Alemtuzumab, Fingolimod - Multiple Sclerosis | Active not recruiting | Biogen | 1178 | 2021-09-24 | 2026-10-15 | |
| Analysis of MS Patients Who Have Had Greater Than 60 Infusions of Natalizumab Natalizumab - Multiple Sclerosis | Unknown | Multiple Sclerosis Center of Northeastern New York | 42 | 2021-05-06 | 2022-03-24 | |
| Examining Effects of Tysabri on Cognitive Fatigue Using fMRI Tysabri - Multiple Sclerosis, Relapsing-Remitting | Completed | Kessler Foundation | 7 | 2021-03-19 | 2026-08-11 | |
| Real World Effectiveness of Natalizumab Extended Interval Dosing in a French Cohort Natalizumab Injection [Tysabri] - Multiple Sclerosis, Relapsing-Remitting | Completed | University Hospital, Caen | 500 | 2020-09-01 | 2022-03-09 | |
| Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS) Autologous Hematopoietic Stem Cell Transplantation, Best Available Therapy (BAT) - Relapsing Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis | Phase 3 | Recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 156 | 2020-08-17 | 2026-10-20 |
| Methylprednisolone During the Switch Between Natalizumab and Fingolimod Methylprednisolone, Placebo, natalizumab (NTZ) - Multiple Sclerosis | Phase 4 | Unknown | University Hospital, Clermont-Ferrand | 56 | 2019-06-12 | 2023-01-09 |
| Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS Early Highly Effective Therapies Group, Escalation Therapies Group - Multiple Sclerosis, Relapsing-Remitting | Phase 4 | Active not recruiting | The Cleveland Clinic | 800 | 2019-01-03 | 2026-08-31 |
| TOPIK Study: A Study to Report Progressive Multifocal Leukoencephalopathy and Other Serious Opportunistic Infections in Natalizumab Treated Participants Natalizumab - Multiple Sclerosis | Completed | Biogen | 675 | 2019-01-01 | 2025-05-13 |
Showing 20 of 91. Sign in to see all of them.
Multiple Sclerosis (37) · Multiple Sclerosis, Relapsing-Remitting (37) · Crohn Disease (8) · Multiple Sclerosis, Chronic Progressive (4) · Arthritis, Rheumatoid (2) · Graft vs Host Disease (2) · Ischemic Stroke (2) · Leukoencephalopathy, Progressive Multifocal (2) · Anemia, Sickle Cell (1) · Autoimmune Diseases (1) · Autoimmune Diseases of the Nervous System (1) · Carcinoma, Basal Cell (1) · Charcot-Marie-Tooth disease, Type 1F (1) · Colitis (1) · Demyelinating Diseases (1)
Biogen (59) · Amsterdam UMC, location VUmc (1) · Beijing Tiantan Hospital (1) · Case Comprehensive Cancer Center (1) · Claudio Gobbi (1) · Copenhagen University Hospital, Rigshospitalet (1) · Cornerstone Health Care, PA (1) · Dana-Farber Cancer Institute (1) · IMPULS Endowment Fund (1) · John Levine (1) · Johns Hopkins University (1) · Karolinska Institutet (1) · Kessler Foundation (1) · King's College London (1) · Multiple Sclerosis Center of Northeastern New York (1)
United States (50) · Germany (16) · France (13) · United Kingdom (12) · Spain (11) · Belgium (10) · Canada (9) · Czechia (9) · Italy (9) · Australia (6) · Netherlands (6) · Sweden (6) · Switzerland (5) · Denmark (4) · Finland (4)
Michael Panzara, MD, MPH (3) · Anders Svenningsson, MD, PhD (1) · Anna Fogdell-Hahn, PhD (1) · Annette Langer-Gould, MD, PhD (1) · Bianca Weinstock-Guttman, MD (1) · Chris Polman, MD (1) · Claudio Gobbi, Dr med. (1) · Corey Cutler, MD, MPH (1) · Daniel Ontaneda, MD, MSc (1) · David Brassat, MD, PhD (1) · Edan Gilles, MD PhD (1) · Ellen M. Mowry, MD, MCR (1) · Eve Versage (1)
PMID 16267322, PMID 37173129, PMID 16510744, PMID 16510745, PMID 20737510, PMID 20737514, PMID 22194217, PMID 22521274, PMID 23555589, PMID 23915113, PMID 24378984, PMID 24532785, PMID 24576156, PMID 24898925, PMID 25755648, PMID 26049148, PMID 27921221, PMID 28078634, PMID 28104251, PMID 28229893, PMID 29524759, PMID 29545067, PMID 30050529, PMID 31176355, PMID 32234967, PMID 32591475, PMID 33082194, PMID 33469828, PMID 34014549, PMID 34376508, PMID 34521687, PMID 34603507, PMID 35483387, PMID 35720980, PMID 36064841, PMID 36727105, PMID 36763307, PMID 36780107, PMID 36966440, PMID 37235690, PMID 37652990, PMID 38469809, PMID 38616781, PMID 38648580, PMID 38654416, PMID 38744460, PMID 39046635, PMID 39393045, PMID 39855661, PMID 41326319
2015 (2), 2008 (1), 2014 (1), 2017 (1), 2018 (1), UM1AI109565 (1)